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Abstract
Background: Atrioventricular block (AVB) is a well-reported complication after closure of perimembranous
ventricular septal defects (VSDs). To report the occurrence of AVB either during or following closure of
perimembranous VSDs using a novel “hybrid” method involving a minimal inferior median incision and of
intraoperative device closure of the perimembranous VSDs.
Methods: Between January 2009 and January 2011, patients diagnosed with perimembranous VSDs eligible for
intraoperative device closure with a domestic occluder were identified. All patients were assessed by real-time
transesophageal echocardiography (TEE) and electrocardiography.
Results: Of the 97 included patients, 94 were successfully occluded using this approach. Complete AVB occurred in
only one case and one case of Mobitz type II AVB was diagnosed intraoperatively. In both patients, the procedure
was aborted and the AVBs quickly resolved. Glucocorticosteroids were administered to another two patients who
developed Mobitz type II AVB intraoperatively. Those two patients converted to Mobitz type I AVB 3 days and 5
days postsurgically. During the follow-up period (range, 6-24 months), one patient developed complete AVB 1
week following device insertion. Surgical device removal was followed by a rapid and complete recovery of
atrioventricular conduction.
Conclusions: Intraoperative device closure of perimembranous VSDs with a domestic occluder resulted in excellent
closure rates; however, AVB is a serious complication that can occur either during or any time after device closure
of perimembranous VSDs. The technique described herein may reduce the incidence of perioperative AVB
complications. Surgeons are encouraged to closely monitor all patients postsurgically to ensure AVB does not
occur in their patients. Additional long-term data to better identify the prevalence and risk factors for AVB in
treated patients are needed.
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Background
Ventricular septal defects (VSD) are one of the most
common congenital cardiac lesions. In the majority of
cases (approximately 70%), VSDs are located in the area
of the perimembranous region wedged between the tri-
cuspid and aortic valves [1]. As an alternative to tradi-
tional surgical closure techniques, transcatheter closure
of VSDs has gradually matured, especially since the
introduction of the Amplatzer occlude. Transcatheter
closure is minimally invasive, offers a good cosmetic
outcome, and is often more acceptable to patients and
their families than traditional surgical approaches [2-5].
Short- and medium-term follow-up data indicate that
many of the shortcomings associated with device clo-
sures have been addressed. In those reports, the most
significant complication was a transient arrhythmia. In
patients with perimembranous VSDs treated via trans-
catheter closure, complete atrioventricular block (AVB)
has been reported [6-10]. The purposes of this article
were to report the incidence of AVB both during and
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VSDs with a domestic occluder and the outcome of
patients who experienced this complication.
Methods
Patients
Between January 2009 and January 2011, patients diag-
nosed with perimembranous VSDs undergoing intrao-
perative device closure with a domestic VSD occluder
were identified. All patients with perimembranous VSDs
measuring 5-12 mm in diameter with a rim > 2 mm
away from nearby major cardiac structures (such as the
aortic, tricuspid, and pulmonary valves) and no evidence
of aortic regurgitation were included. Patients eligible
for intraoperative device closure had hemodynamically
significant left-to-right shunts, significant chamber
enlargement, mild-moderate pulmonary hypertension
despite medical therapy, and a history of infective endo-
carditis. Patients with VSDs in other locations or with
coexisting cardiac anomalies were excluded. Routine
preoperative examinations included a standard electro-
cardiogram, thoracic radiographs, and blood tests.
Devices
The device delivery system consists of a trocar, guide
wire, a dilator and delivery sheath, and a loading sheath
made of polyethylene and acrylonitrile butadiene styrene
and disinfected with ethylene oxide. The VSD occluder
is a self-expandable, double-disk device. (Lifetech Scien-
tific (Shenzhen) Co, Ltd and Shanghai Shape Memory
Alloy Co, Ltd., China) As shown in Figure 1, both asym-
metric and symmetric occluders were employed. On the
left ventricular side of the asymmetric device, the aortic
end of the disk is 1 mm wider than the waist to avoid
impinging the aortic valve whereas the other side is
positioned to be 5-6 mm wider than the waist and has a
platinum marker to guide device orientation. For the
symmetric device, the left ventricular disk is 2 mm lar-
ger than the waist. The right ventricular disk is 2 mm
larger than the waist in both occluders. The occluders
are sized according to the waist diameters, which range
from 4 mm to 16 mm in 1 mm increments. The occlu-
ders were implanted using a 6-9 F delivery sheath.
Protocol
In all patient the presence of a VSD was confirmed pre-
procedurally using transthoracic echocardiography
(TTE) with color Doppler from the subxyphoid, apical,
and parasternal views. During device deployment, TEE
(GE vivid 7, GE Medical Systems, Milwaukee, WI, USA)
was used for accurate determination of the VSD loca-
tion, morphologic features, size (the largest diameter),
and for visualization of the rims. The diameter of the
VSD was measured by TTE using two-dimensional ima-
ging and color flow Doppler on both the long and short
axis views. General anesthesia was induced in all
patients, who were subsequently placed in a supine posi-
tion and draped for exposure to the entire thoracic cav-
ity. Intraoperative TEE was used to assess the
perimembranous VSD, particularly the defect size and
circumferential margins adjacent to the aortic and tri-
cuspid valves. An appropriately sized occluder was
selected based on the largest size of the defect on TEE
color Doppler imaging. Where the defect was aneurys-
mal or fenestrated, the maximum size of the mouth of
the aneurysm (true VSD) was recorded as well as the
exit point of the main defect into the right ventricle.
The asymmetric device had a margin 0-2 mm in excess
of the aortic rim.
An inferior median sternotomy was created (3-5 cm)
and a small rib spreader was used to manipulate the
incision and facilitate instrumentation. The pericardium
was opened and suspended to expose the right ventricle.
On the free wall of the right ventricle two parallel 5-0
or 4-0 prolene sutures were placed and 1 mg/kg IV
heparin was administered to maintain an activated clot-
ting time > 250 sec. A modified short angiocatheter was
passed into the right ventricle through the free wall and
then the needle was removed. A floppy wire was
advanced through the angiocatheter in the direction of
the perimembranous VSD (Figure 2). The VSD was
crossed and the wire was advanced through the defect
into the left ventricle. The dilator was removed, and an
appropriately sized delivery sheath was advanced over
the wire into the left ventricle. The wire and the dilator
were removed, and the sheath was allowed to back
bleed to ensure there was no air entrapment (Figure 3).
The VSD occluder was immersed in saline and screwed
onto the delivery cable. The device was loaded with a
Figure 1 The asymmetric device, the symmetric device, and
the entire delivery system.
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the delivery sheath. The occluder was advanced to the
tip of the sheath, and the sheath was gently pulled back
until the tip was in the left ventricle. Under echocardio-
graphic guidance, the left disc was deployed and the
sheath was pulled back slowly until the left disc approxi-
mated the ventricular septum (Figure 4). To implant the
asymmetric device, the device was gently rotated so the
platinum marker of the distal disk pointed down and
the flat part of the disc was not directly under the aortic
valve. The waist and the right disc of the occluding
device were deployed while maintaining traction on the
delivery cable (Figure 5). TEE was repeated to ensure no
significant residual shunt or aortic or tricuspid valve
regurgitation. The occluder was then released by rotat-
ing the delivery cable counterclockwise. The sheath and
the delivery cable were withdrawn. Closure was routine,
and no drainage tube was necessary. Oral dipyridamole
or aspirin were prescribed for 3-6 months for anticoagu-
lation [11].
The present study was approved by the ethics com-
mittee of the authors’ university and adhered to the
tenets of the Declaration of Helsinki. Additionally, the
w r i t t e ni n f o r m e dc o n s e n tw a so b t a i n e df r o mt h e
patients or their parents.
Statistical analysis
Continuous data were presented as mean ± standard
deviation and range.
Results
In total, 97 patients (42 males) underwent intraoperative
device closure treatment. Mean patient age was 13.2 ±
11.8 years (range, 1-56 years) and mean body weight
was 34.1 ± 16.9 kg (range, 8.5-70 kg). Delivery of the
occluder was successful in 94 patients. Mean size of the
perimembranous VSD measured by TEE was 7.6 ± 1.6
mm (range, 5-12 mm). Mean size of the implanted
Figure 2 A floppy wire positioned from the right ventricle free
wall into the left ventricle cavity across the VSD.
Figure 3 A sheath was advanced over the wire into the left
ventricle across the VSD.
Figure 4 The left disc was deployed.
Figure 5 Final image showed after a device was deployed.
Chen et al. BMC Cardiovascular Disorders 2012, 12:21
http://www.biomedcentral.com/1471-2261/12/21
Page 3 of 6occluders was 8.8 ± 1.9 mm (range, 6-14 mm) and the
diameter of the sheath ranged from 6-9 F.
Intraoperatively, complete AVB occurred in one
patient and a Mobitz type II AVB occurred in one
patient. In both patients, the AVB resolved quickly after
discontinuing the procedure. In addition, two patients
developed Mobitz type II AVB intraoperatively. Because
those two patients intermittently recovered sinus
rhythm, temporary pacemakers were inserted. After the
administration of glucocorticoids, the two patients with
Mobitz type II AVB converted to Mobitz type I AVB in
3 and 5 days.
Immediately postprocedurally, Mobitz type I AVB was
observed in two patients. No intervention was required,
but patients were closely observed. One patient pre-
sented with complete AVB 1 week after device insertion.
Surgical device removal was followed by a rapid and
complete recovery of atrioventricular conduction.
In addition to the AVBs noted above, minor transient
arrhythmias were encountered in 12 patients during the
course of device deployment, including temporary sinus
bradycardia, atrial premature beats, and transient left
bundle branch block. All of those minor arrhythmias
either spontaneously resolved or were easily and suc-
cessfully treated pharmacologically.
The mean and median follow-up period was 1.37 ±
0.56 years and 1 year, respectively (range, 6 months to 2
years) for patients in which the occluders were success-
fully implanted. Outpatient follow-up was achieved with
functional, echocardiographic, and electrocardiographic
assessment. No progressive arrhythmias were noted dur-
ing the follow-up period. To date, none of the patients
in the study cohort developed complete AVB.
Discussion and Conclusions
VSD is one of the most common congenital cardiac
defects. Elective open-heart repair with midline sternot-
omy and cardiopulmonary bypass has been considered
the gold standard for the closure of the perimembra-
nous VSD; however, with the advent of various devices
and techniques, percutaneous transcatheter occlusion of
the VSD has gradually become a viable option for select
patients. The safety and feasibility of transcatheter clo-
sure of a perimembranous VSD using Amplatzer septal
occluders in many centers has been demonstrated, and
complications seem to be limited [12-15]. At the
authors’ institute, a hybrid method (described by Xing
Quansheng and his colleagues’) is employed to close
perimembranous VSDs, which includes the use of an
intraoperative device and minimally invasive approach
[16,17]. Similar to other reports of transcatheter closure
of perimembranous VSDs, we have also achieved high
technical success and good outcomes. Due to the close
proximity of the perimembranous VSD to the
conduction system, however, one complication that can
occur is AVB. Recently, an increasing number of studies
have begun to focus on this complication.
Complete AVB is an uncommon complication of con-
genital heart disease surgery. According to Tucker,
operative AVB and permanent pacemaker placement
occurred in 1.1% and 0.8% of their patients, respectively,
which is comparable to those currently considered for
device closure of the perimembranous VSD. A perma-
nent pacemaker is reportedly more likely in patients
with Down syndrome and in younger patients [18].
Andersen and his colleagues reported that iatrogenic
complete AVB continued to occur after surgical VSD
closure either because of unexpected biological varia-
tions or because of a lack of awareness of the disposi-
tion of the atrioventricular conduction axis in particular
circumstances. That report addresses the atrioventricular
conduction axis and suggests that the risk of iatrogenic
complete AVB is < 1% [19]. Although not common, sur-
geons’ awareness of this potential complication and
increased experience performing the surgical technique
likely have reduced the incidence of complete AVB.
Pacemaker insertion is usually recommended if there is
no recovery of the atrioventricular conduction either
intra- or postoperatively. As opposed to complete AVBs
that occur intraoperatively, complete AVBs can occur
days, weeks, or even months later following device
deployment. Sporadic studies have reported the inci-
dence of transient complete AVBs in up to 1-5% of
patients undergoing transcatheter device closure of peri-
membranous VSDs. For example, Zhou et al. reported
the incidence of AVB occurring either during or after
transcatheter closure of perimembranous VSDs was
3.5% in a series of 168 patients that included a 6-24
month follow-up period [9]. In a study by Butera and
colleagues, two patients (2.5 years and 4 years of age)
treated with eccentric VSD occluder devices developed
c o m p l e t eA V Bt h a tw a sd i a g n o s e d4a n d1 2m o n t h s
postprocedurally. Both subjects underwent endocardial
ventricular pacemaker implantation [7]. Predescu and
colleagues reported that acute complete shunt occlusion
was achieved in all patients, but during the median fol-
low-up period of 23.1 months (range, 1-37.8 months),
four patients (22%) had complete AVB 17 days, 4.2
months, 8.8 months, and 37.5 months after implanta-
tion. No risk factors were identified for development of
complete AVB. Thus, although that study reported a
high technical success with 100% shunts ultimately
occluded, an unacceptably high rate of complete AVB
occurred. Based on that data, perimembranous VSD
device implantation was terminated at that medical
institution [10]. Compared with Predescu et al.’s data,
the incidence of complete AVB was only 2.1% in the
current study.
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past; however, the exact underlying mechanism(s) of
AVB remain(s) speculative. It is in the perimembranous
ventricular septal area that the atrioventricular conduc-
tion bundle emerges from the central fibrous body to
become subendocardial. Thus, due to its anatomic loca-
tion, the atrioventricular conduction bundle may be
prone to damage during correction of VSDs. Conduc-
tion system injury from mechanical trauma/compression
by either the delivery system or the device itself can
potentially cause acute intraprocedural complete AVB.
Some cases of early complete AVB were resolved spon-
taneously, with short-term corticosteroid therapy, or
device removal [8,9,20]. In the authors’ experience, com-
plete AVB occurred in only one case (in addition to the
one Mobitz type II AVB) during the procedure. In both
of those cases the intraoperative AVBs disappeared
quickly after discontinuing the procedure. Despite the
limited number of AVB cases, these results have led the
authors to believe that AVB occurring immediately after
device occlusion may result directly from mechanical
trauma/compression to the conduction system. The
authors recommended abandoning the procedure if
complete AVB occurs, ensuring that the defect is care-
fully traversed with the delivery sheath. Careful manipu-
lation of devices when crossing the defect is likely
imperative to avoid AVB.
In addition, the surgical approach described herein
provides cardiac surgeons with a perpendicular angle to
the perimembranous ventricular septum, which may
facilitate guiding the wire through the VSD and deploy-
ing the occluder into the defect without causing any
trauma to the atrioventricular conduction pathway. This
is evidenced by the small number of patients who devel-
oped AVBs in this study. The size and position of the
device must be carefully verified via TEE both before
and after deployment. The selected device should be
either the same size or only 1-2 mm larger than the
VSD (as determined by the TEE). From the little evi-
dence that we have to date, the use of an oversized
device should be avoided.
One study has suggested that smaller patients might
be at higher risk for AVB than older patients [10]. In
the current study, the one case of complete AVB that
occurred Intraoperatively was a 4 year old boy. His VSD
measured 5 mm in diameter and a 6 mm occluder was
deployed in this case. Clearly, age is not likely the only
issue and additional risk factors need to be identified.
Indeed, it remains unclear why certain patients develop
complete AVB and others do not and why the AVB
occurs intraoperatively in some patients but either early
or late in the postoperative period in others. It is possi-
ble that AVBs that occur weeks to months after device
deployment could be due to inflammation and fibrosis.
Occluders have been shown to cause a localized inflam-
matory reaction that can result in extensive scar tissue
and cartilaginous metaplasia of the surrounding myocar-
dium [6]. A number of studies have reported on the late
onset of complete AVB [7,21]. Chen for example report
one case of delayed complete AVB with severe tricuspid
regurgitation occurring 5 years after implantation of an
eccentric Amplatzer perimembranous VSD occluder
[22]. Similarly, Yalonetsky et al. presented a patient who
developed symptomatic Mobitz type II AVB 3 years fol-
lowing percutaneous closure of such a defect [23].
Device flattening or shifting is another mechanism that
may be responsible for some of the late instances of
AVB. In the current study, a 6 year old boy treated with
an 8 mm occluder developed complete AVB 1 week
postprocedurally. Device removal together with surgical
VSD closure was immediately performed, followed by a
rapid and complete recovery of normal atrioventricular
conduction. During the surgical closure, the right ventri-
cular disc was found impinging on the septum. It is pos-
sible that this device shift disturbed the atrioventricular
conduction by direct traumatic compression. Patients
and their parents should therefore be informed regard-
ing the risk of sudden, potentially life-threatening late-
onset complete AVB. Long-term follow-up, perhaps life-
long follow-up, may be indicated (or mandatory) in
patients that have had occluders implanted for VSDs.
Based on this study, the chances of developing delayed-
onset complete AVB are the same regardless of the sur-
gical approach.
Although it is not clear how AVB can be avoided in
patients with VSDs, the authors recommended abandon-
ing the procedure if complete AVB occurs. Some
authors suggest that a course of steroids may be useful
in reversing AVB [6,8], but the effectiveness of these
drugs has yet to be determined. Nonetheless, we admi-
nistered corticosteroids to the two patients with Mobitz
type II AVB. These two patients recovered sinus rhythm
intermittently during the operation, so temporary pace-
makers were inserted in these patients. These two
patients subsequently improved (to Mobitz type I AVB)
in 3 and 5 days. Implantation of permanent pacemakers
and timing of implantation remain controversial topics.
In our opinion, surgical closure remains the best treat-
ment of choice for patients who present with complete
AVB.
This single-center experience included only a small
number of patients. Nonetheless, this study notes that
complete AVB can occur either during the course of
device closure of the perimembranous VSDs or post-
operatively. This study is not, however, representative of
the entire perimembranous VSD device experience,
which includes many older and larger patients and smal-
ler defects. All of the VSDs in this study were restrictive.
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a low-income region where health care resources are
limited. Although device closure of perimembranous
VSDs appear to be safe in the short-term, it remains
unknown whether they are safe in the very long-term.
Given these circumstances, longer follow-up data are
needed.
In conclusion, this study demonstrates that intraopera-
tive device closure of perimembranous VSDs is safe and
feasible based on short-term follow-up data. Complete
AVB is a serious complication that can occur both dur-
ing and after device closure. No risk factors for com-
plete AVB were identified in this study. Additional
multi-center studies are needed, and long-term follow-
up is essential for all patients who have had devices
implanted.
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